Esco Aster provides experienced fractional executives and interim leadership to biotechnology, bioindustry, pharmaceutical, cell therapy, gene therapy, nutrition, dermocosmetic, nutricosmetic and medical technology companies.
Our leaders integrate directly into client organizations as members of the executive leadership team, providing strategic and operational leadership during critical stages of growth, fundraising, clinical development, commercialization, or organizational transition.
Unlike traditional consulting engagements that operate externally, our interim executives function as accountable members of the management team, empowered by the Board and executive leadership to make decisions, execute strategy, and deliver measurable outcomes.
Fractional leadership is particularly valuable for startups and emerging companies that require executive-level expertise but do not yet justify or cannot afford a full-time C-suite appointment. It also provides continuity during leadership transitions, ensuring that business momentum, regulatory activities, and investor confidence are maintained.
Leadership gaps can significantly disrupt operations, delay strategic decisions, increase cash burn, compromise regulatory compliance, and jeopardize financing milestones. In cell and gene therapy, where manufacturing processes define the product itself and development timelines are highly compressed, rapid, informed decision-making is essential. Companies require leaders with proven experience who can balance scientific excellence, regulatory compliance, operational execution, fundraising, and commercial strategy.
Our interim executives provide the leadership needed to maintain operational continuity, achieve clinical and investment milestones, and position companies for successful commercialization, strategic partnerships, or exit.
Biotechnology companies operate in one of the world's most complex and highly regulated industries. Executive decisions must simultaneously consider scientific development, manufacturing readiness, quality systems, regulatory strategy, capital efficiency, and long-term commercial objectives.
Companies developing cell therapies, gene therapies, biologics, nutraceuticals, dermocosmetics, and advanced therapeutics require leaders who combine deep technical expertise with broad commercial and operational experience.
Our interim executives provide:
- Immediate access to experienced C-suite leadership without lengthy recruitment cycles.
- Sector-specific expertise spanning scientific, regulatory, manufacturing, clinical, commercial, and fundraising functions.
- Executive oversight to balance operational execution with financial discipline and investor expectations.
- Strategic leadership across product development, manufacturing scale-up, commercialization, and corporate growth.
- Regulatory expertise to navigate rapidly evolving country-specific requirements while minimizing delays in IND, CTA, BLA, or market authorization submissions.
- Proven playbooks that reduce execution risk, improve capital allocation, strengthen operational efficiency, and accelerate milestone achievement.
Without experienced executive leadership, companies risk inefficient deployment of capital, delayed development timelines, missed non-dilutive funding opportunities, regulatory setbacks, and reduced enterprise value.
Every engagement is tailored to the company's stage of development, technology platform, and strategic objectives.
Our fractional executives integrate seamlessly into existing leadership teams, providing immediate strategic direction while remaining accountable for agreed deliverables throughout the engagement.
Our expertise includes:
Interim CEO, Chairman, COO, CTO, CSO, CMO, CFO and other executive positions.
- corporate strategy and organizational leadership
- Board advisory and governance
- Business continuity during leadership transitions
- Corporate restructuring and organizational scaling
- Fundraising strategy and investor engagement
- Strategic partnerships and licensing
- Corporate development and business development
- Investment milestone planning
- Exit strategy and commercialization planning
- Chemistry, Manufacturing & Controls (CMC)
- Process development and process engineering
- Manufacturing strategy (in-house versus outsourced)
- MSAT and technology transfer
- Facility planning, engineering oversight, and manufacturing scale-up
- Process qualification and validation
- Analytical development and Quality Control
- IND/CTA/BLA regulatory strategy
- Gap assessments and regulatory readiness
- cGMP, GMP and ISO compliance
- Quality Management Systems (QMS)
- Quality Assurance and Quality Control oversight
- Clinical quality systems
- Validation strategy
- Global regulatory coordination
- Product development strategy
- Non-clinical and clinical development planning
- Technical due diligence
- Development roadmap optimization
- Cross-functional scientific leadership
Where additional specialist expertise is required, Esco Aster maintains an international network of experienced industry experts and subject matter specialists who can be deployed as part of the engagement.
Depending on client requirements, our engagements may include:
- Fractional C-suite and executive leadership
- Strategic business and operational decision support
- Business continuity planning during executive transitions
- Corporate governance and Board advisory
- Fundraising strategy and investor readiness
- CMC strategy and manufacturing leadership
- Process development and engineering oversight
- Regulatory strategy and submission support
- Quality systems implementation and GxP compliance
- Risk management and operational excellence
- Commercialization and exit planning
- Access experienced executives without long-term employment commitments.
- Preserve equity by avoiding unnecessary founder dilution or executive sweat equity.
- Improve capital efficiency through milestone-driven leadership.
- Increase confidence that investment milestones are achieved on schedule.
- Gain immediate executive capability without permanent payroll costs.
- Maintain operational continuity during leadership transitions.
- Scale leadership resources according to company growth and project needs.
- Accelerate execution while minimizing organizational disruption.
- Strengthen governance through experienced executive oversight.
- Reduce strategic and operational risk during periods of rapid growth.
- Ensure alignment between scientific, regulatory, financial, and commercial objectives.
- Improve organizational readiness for financing, partnerships, and acquisitions.
- Maintain compliance with evolving global GxP, GMP, cGMP, ISO, and regulatory requirements.
- Reduce risks associated with delayed IND, CTA, BLA, or commercial approvals.
- Strengthen quality systems and inspection readiness throughout the product lifecycle.
Our interim leadership can be deployed across a wide range of executive functions, including:
- Interim CEO or Executive Chairman to lead fundraising, corporate restructuring, and strategic growth.
- Interim Chief Medical Officer (CMO) to support clinical development and IND submissions.
- Interim Chief Scientific Officer (CSO) to oversee product development and scientific strategy.
- Interim Chief Technology Officer (CTO) to lead CMC, process development, and manufacturing strategy.
- Interim Head of Engineering to oversee facility design, engineering assessments, and capacity expansion.
- Interim Head of Quality to establish Quality Management Systems and regulatory compliance.
- Interim Head of Validation or Process Engineering to lead process qualification and validation.
- Interim Head of MSAT to define technology transfer, scale-up, and commercial manufacturing strategy.
- Interim Chief Financial Officer (CFO) to strengthen financial controls, ERP implementation, fundraising support, and financial planning.
Esco Aster's Fractional Talent & Interim Leadership services provide immediate access to seasoned biotechnology executives who combine scientific excellence with operational execution, regulatory expertise, commercial insight, and fundraising experience.
By embedding experienced leaders directly within client organizations, we help companies accelerate development, preserve capital, reduce execution risk, achieve investment milestones, and maximize enterprise value from early development through commercialization and successful exit.
- Quality Target Product Profile (QTPP) & CMC Strategy
- Investor & Technical Due Diligence
- Fundraising Strategy
- Pitch Deck & Data Room Development